References
- Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M,
Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G,
McCubrey JA. New landscapes and horizons in hepatocellular carcinoma
therapy. Aging (Albany NY) 2020; 12: 3053-3094. doi:
10.18632/aging.102777
- Luo J, Gao B, Lin Z, Fan H, Ma W, Yu D, Yang Q, Tian J, Yang X, Li B.
Efficacy and safety of lenvatinib versus sorafenib in first-line
treatment of advanced hepatocellular carcinoma: A meta-analysis.Front Oncol. 2022; 12:1010726. doi: 10.3389/fonc.2022.1010726
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder
V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang
C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150
Investigators. Atezolizumab plus Bevacizumab in Unresectable
Hepatocellular Carcinom. N Engl J Med . 2020; 382:1894-1905.
doi: 10.1056/NEJMoa1915745
- Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz
B, Simantov R, Kelley S. Discovery and development of sorafenib: a
multikinase inhibitor for treating cancer, Nat Rev Drug Disc .
2006; 5:835-44. doi: 10.1038/nrd2130
- Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE.
PharmGKB summary: sorafenib pathways, Pharmacogenet Genomics .
2017; 27:240-246. doi: 10.1097/FPC.0000000000000279
- Terada T, Noda S, Inui K. Management of dose variability and side
effects for individualized cancer pharmacotherapy with tyrosine kinase
inhibitors. Pharmacol Ther . 2015; 152:125-134. doi:
10.1016/j.pharmthera.2015.05.009
- Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi
FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M,
Casadei Gardini A. Ten Years of Sorafenib in Hepatocellular Carcinoma:
Are there any Predictive and/or Prognostic Markers? World J
Gastroenterol . 2018; 24:4152-4163. doi: 10.3748/wjg.v24.i36.4152
- Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes,
consequences, challenges and opportunities. Cell Mol Life Sci. 2020;
77:1745-1770. doi: 10.1007/s00018-019-03351-7
- Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone
M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C,
Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti
E, Ulivi P, Frassineti GL. ENOS Polymorphisms and Clinical Outcome in
Advanced HCC Patients Receiving Sorafenib: Final Results of the ePHAS
Study. Oncotarget 2016; 7:27988-27999. doi:
10.18632/oncotarget.8569
- Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi
G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas
L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A,
Cascinu S, Scartozzi M. Angiogenesis Genotyping and Clinical Outcomes
in Patients with Advanced Hepatocellular Carcinoma Receiving
Sorafenib: The ALICE-2 Study. Target Oncol . 2020; 15:115-126.
doi: 10.1007/s11523-020-00698-x
- Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L,
Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L,
Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M,
Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V,
Cascinu S, Scartozzi M. Association of NOS3 and ANGPT2 Gene
Polymorphisms with Survival in Patients with Hepatocellular Carcinoma
Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE
Study. Clin Cancer Res . 2020; 26:4485-4493. doi:
10.1158/1078-0432.CCR-19-3897
- Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro
M, Tassone P, Tagliaferri P. DMET (Drug Metabolism Enzymes and
Transporters): A pharmacogenomic platform for precision medicine.
Oncotarget 2016; 8:54028-54050. doi: 10.18632/oncotarget.9927
- Arbitrio M, Scionti F, Di Martino MT, Caracciolo D, Pensabene L,
Tassone P, Tagliaferri P. Pharmacogenomics Biomarker Discovery and
Validation for Translation in Clinical. Practic Clin Transl
Sci . 2021; 14: 113-119. doi: 10.1111/cts.12869
- Scionti F, Di Martino MT, Caracciolo D, Pensabene L, Tagliaferri P,
Arbitrio M. Tools in Pharmacogenomics Biomarker Identification for
Cancer Patients. Methods Mol Biol. 2022; 2401:1-12. doi:
10.1007/978-1-0716-1839-4_1
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for
hepatocellular carcinoma. Semin Liver Dis . 2010; 30:52-60. doi:
10.1055/s-0030-1247132
- Bruix J, Sherman M. American Association for the Study of Liver
Diseases. Management of hepatocellular carcinoma: an update.Hepatology . 2011; 53:1020-1022. doi: 10.1002/hep.24199
- European Association For The Study Of The Liver; European Organisation
For Research And Treatment Of Cancer. EASL-EORTC clinical practice
guidelines: management of hepatocellular carcinoma, J. Hepatol. 56
(2012) 908-943. doi: 10.1016/j.jhep.2011.12.001
- Scionti FPL, Di Martino MT, Arbitrio M, Tagliaferri P. Ethical
Perspectives on Pharmacogenomic Profiling. Elsevier. Amsterdam, The
Netherlands, 2021.
- Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K,
Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D,
Pensabene L. Genetic variants associated with Fabry disease
progression despite enzyme replacement therapy, Oncotarget .
2017; 8:107558-107564. doi: 10.18632/oncotarget.22505
- Scionti F, Agapito G, Caracciolo D, Riillo C, Grillone K, Cannataro M,
Di Martino MT, Tagliaferri P, Tassone P, Arbitrio M. Risk Alleles for
Multiple Myeloma Susceptibility in ADME Genes. Cells . 2022;
11:189. doi: 10.3390/cells11020189
- Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano
T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D,
Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity
and Have Prognostic Relevance in Patients With Breast Cancer: A
Case-Control Study, Clin Pharmacol Ther. 2019; 106:422-431.
doi: 10.1002/cpt.1391
- Cargnin S, Viana M, Sances G, Cantello R, Tassorelli C, Terrazzino S.
Using a Genetic Risk Score Approach to Predict Headache Response to
Triptans in Migraine Without Aura. J Clin Pharmacol . 2019;
59:288-294. doi: 10.1002/jcph.1320
- Du B, Zhang C, Yue L, Ren B, Zhao Q, Li D, He Y, Zhang W. Prediction
model for the efficacy of folic acid therapy on hyperhomocysteinaemia
based on genetic risk score methods. Br J Nutr . 2019;
122:39-46. doi: 10.1017/S0007114519000783
- Gagno S, D’Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E,
Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M,
Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R,
Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P,
Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G,
Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM,
Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G. A New Genetic
Risk Score to Predict the Outcome of Locally Advanced or Metastatic
Breast Cancer Patients Treated With First-Line Exemestane: Results
From a Prospective Study. Clin Breast Cancer . 2019; 19:137-145.
doi: 10.1016/j.clbc.2018.11.009
- Faloppi L, Casadei Gardini A, Masi G, Silvestris N, Loretelli C, Ulivi
P, Vivaldi C, Bianconi M, Giampieri R, Bittoni A, Andrikou K, Del
Prete M, Scartozzi M, Cascinu S. Angiogenesis polymorphisms profile in
the prediction of clinical outcome of advanced HCC patients receiving
sorafenib: Combined analysis of VEGF and HIF-1α Final results of the
ALICE-2 study. J Clin Oncol . 2016; 34:280. doi:
10.1200/jco.2016.34.4_suppl.280
- Guzzi PH, Agapito G, Di Martino MT, Arbitrio M, Tassone P, Tagliaferri
P, Cannataro M. DMET-Analyzer: automatic analysis of Affymetrix DMET
Data. BMC Bioinformatics . 2012; 13:258. doi:
10.1186/1471-2105-13-258
- Agapito G, Milano M, Cannataro M. A statistical network pre-processing
method to improve relevance and significance of gene lists in
microarray gene expression studies. BMC Bioinformatics . 2022;
23:1-20. doi: 10.1186/s12859-022-04936-z
- Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update:
context-specific physical protein-protein interactions in human, model
organisms and domesticated species. Nucleic Acids Res . 2019;
47:581-589. doi: 10.1093/nar/gky1037
- Lee S, Liu Y, Li J, Friedman C, Lussier YA. Discovery of protein
interaction networks shared by diseases. Pac Symp Biocomput .
2007; 76-87.
- Paul S, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
Schwikowski B, Ideker T. Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome
Res . 2003; 13:2498-2504. doi: 10.1101/gr.1239303
- Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. Cytohubba: identifying
hub objects and sub-networks from complex interactome. BMC Syst
Biol. 2014;8 Suppl 4(Suppl 4):S11 doi: 10.1186/1752-0509-8-S4-S11
- Agapito G, Cannataro U. Using BioPAX-Parser (BiP) to enrich lists of
genes or proteins with pathway data. BMC Bioinformatics . 2021;
22:1-35. doi: 10.1186/s12859-021-04297-z
- Rahmati S, Abovsky M, Pastrello CM, Kotlyar M, Lu R, Cumbaa CA, Rahman
P, Chandran V, Jurisica I. pathDIP 4: an extended pathway annotations
and enrichment analysis resource for human, model organisms and
domesticated species. Nucleic Acids Res . 2020; 48:479-488. doi:
10.1093/nar/gkz989
- Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling
pathways governing hepatocellular carcinoma behavior; small
molecule-based approaches. Cancer Cell Int . 2021; 21: 208 doi:
10.1186/s12935-021-01924-w
- Kobayashi K, Higai K, Matsuo K, Bannai Y, Horie H, Otakara Y, Li W,
Koike K, Yanagino S, Watanabe K, Yoshio T, Wakui N, Nagai H.
Quantitative Measurements of Sorafenib in Patients with Advanced
Hepatocellular Carcinoma. Int J Res Stud Med Health Sci. 2018;
3:14-19.
- Ruggiero D, Dalmasso C, Nutile T, Sorice R, Dionisi L, Aversano M,
Bröet P, Leutenegger AL, Bourgain C, Ciullo M. Genetics of VEGF serum
variation in human isolated populations of cilento: importance of VEGF
polymorphisms. PLoS One . 2011; 6:e16982. doi:
10.1371/journal.pone.0016982
- Al-Habboubi HH, Mahdi N, Abu-Hijleh TM, Abu-Hijleh FM, Sater MS,
Almawi WY. The relation of vascular endothelial growth factor (VEGF)
gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis
in sickle cell disease, Eur J Haematol . 2012; 89:403-409. doi:
10.1111/ejh.12003
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de
Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C,
Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I,
Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J;
SHARP Investigators Study Group. SHARP Investigators Study Group
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med .
2008; 24:378-390. doi: 10.1056/NEJMoa0708857
- Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J,
Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N,
Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F,
Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari
D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S,
Frassineti GL, Scartozzi M. Multicenter prospective study of
angiogenesis polymorphism validation in HCC patients treated with
sorafenib. An INNOVATE study protocol. Tumori . 2018;
104:476-479. doi: 10.5301/tj.5000704
- Fang X, Liu Y, Xiao W, Zhao N, Zhu C, Yu D, Zhao Y. Prognostic SLC
family genes promote cell proliferation, migration, and invasion in
hepatocellular carcinoma. Acta Biochim Biophys Sin. (Shanghai) .
2021; 53:1065-1075. doi: 10.1093/abbs/gmab076
- Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H,
Martinez-Picado J, Pastor-Anglada M. Role of Human Organic Cation
Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and
Drug-Drug Interactions. Front Pharmacol . 2016; 7:175. doi:
10.3389/fphar.2016.00175
- Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan
ZR, Tang J, Chen L, Chen Y. Increased expression of SLC46A3 to oppose
the progression of hepatocellular carcinoma and its effect on
sorafenib therapy. Biomed Pharmacother . 2019; 114:108864. doi:
10.1016/j.biopha.2019.108864
- Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM,
Marin JJ, Briz O. Expression of SLC22A1 variants may affect the
response of hepatocellular carcinoma and cholangiocarcinoma to
sorafenib. Hepatology . 2013; 58:1065-1073. doi:
10.1002/hep.26425
- Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla
R, Marin JJ. The lack of the organic cation transporter OCT1 at the
plasma membrane of tumor cells precludes a positive response to
sorafenib in patients with hepatocellular carcinoma.Oncotarget . 2017; 8:15846-15857. doi: 10.18632/oncotarget.15029
- Liu X, Huang R, Liu X, You H, Kong F, Tang R. Prognostic implications
of alcohol dehydrogenases in hepatocellular carcinoma. BMC
Cancer . 2020; 20:1204. doi: 10.1186/s12885-020-07689-1
- Osanai M, Lee GH. Increased expression of the retinoic
acid-metabolizing enzyme CYP26A1 during the progression of cervical
squamous neoplasia and head and neck cancer. BMC Res Notes .
2014; 7:697. doi: 10.1186/1756-0500-7-697
- Osanai M, Lee GH. The retinoic acid-metabolizing enzyme CYP26A1
upregulates fascin and promotes the malignant behavior of breast
carcinoma cells. Oncol Rep . 2015; 34:850-858. doi:
10.3892/or.2015.4042
- Yu Y, Wang Y, Zou Y, Yu Y. CYP26A1 Is a Novel Cancer Biomarker of
Pancreatic Carcinoma: Evidence from Integration Analysis and In Vitro
Experiments. Dis Markers . 2022; 2022:5286820. doi:
10.1155/2022/5286820
- Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N,
Toriguchi K, Hatano E, Endo K, Hirooka Y, Shiota G. Biological and
clinical implications of retinoic acid-responsive genes in human
hepatocellular carcinoma cells. J Hepatol . 2013; 59:1037-1044.
doi: 10.1016/j.jhep.2013.06.024
- Lotan R. Retinoids as modulators of tumor cells invasion and
metastasis. Semin Cancer Biol. 199;1 2: 197-208.